As more payers demand outcome studies, drug development costs will rise

12/3/2013 | Forbes

Drugmakers increasingly must conduct expensive outcome and comparative effectiveness studies to win not only FDA approval but also to be included on payers' formularies, writes John LaMattina, former president of Pfizer Global Research and Development. "The greater need for outcome studies will strain even the biggest pharmaceutical company R&D budgets," LaMattina writes. Yet outcome studies benefit patients, physicians and payers, and demonstrating the real value of new medicines will increase public confidence in their long-term health benefits, LaMattina writes.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID